Abstract | PURPOSE OF REVIEW: The World Health Organization (WHO) classification of central nervous system (CNS) tumors was revised in 2016 to include molecular biomarkers that are important for tumor classification and clinical decision making. Thereafter, the cIMPACT-NOW initiative further refined CNS tumor classification through a series of recommendations likely to shape the upcoming WHO classification 2021. RECENT FINDINGS: SUMMARY: These changes increase diagnostic accuracy and refine clinical care by changing treatment recommendations, for example for patients with IDH-wildtype astrocytomas showing molecular features of glioblastoma. They also have major implications for clinical trial design.
|
Authors | Michael Weller, Guido Reifenberger |
Journal | Current opinion in neurology
(Curr Opin Neurol)
Vol. 33
Issue 6
Pg. 701-706
(12 2020)
ISSN: 1473-6551 [Electronic] England |
PMID | 33177376
(Publication Type: Journal Article, Review)
|
Chemical References |
- Isocitrate Dehydrogenase
- Telomerase
|
Topics |
- Brain Neoplasms
(classification, genetics, pathology)
- Glioma
(classification, genetics, pathology)
- Homozygote
- Humans
- Isocitrate Dehydrogenase
(genetics)
- Mutation
- Promoter Regions, Genetic
- Sequence Deletion
- Telomerase
(genetics)
- World Health Organization
|